Skip to main content
  1. Courses
  2. Virtual 2020 National Tuber...
  3. LTBI Treatment: Guidelines ...
  4. LTBI Treatment: Guidelines ...

LTBI Treatment: Guidelines and Clinical Recommendations

Thank you

This live web event has ended. Thank you for attending.

Description


LTBI Treatment: Guidelines and Clinical Recommendations

Tuberculosis (TB) prevention is an essential part of the strategy to eliminate TB. In this session, the 2020 NTCA/CDC Latent TB Infection (LTBI) treatment guidelines will be presented along with an in-depth review of the soon-to-be released companion document to the 2020 guidelines, developed by NTCA’s National Society of TB Clinicians (NSTC). This companion document, Testing and Treatment of Latent Tuberculosis Infection in the United States: Clinical Recommendations, was developed by TB clinicians who are national experts in the care and treatment of individuals with TB and LTBI. These expert recommendations for the screening, testing, and treating of LTBI, present a more detailed guide for clinicians and provide extensive treatment recommendations based on best practices and clinical expertise.

NTCA, in partnership with the University of New Mexico’s School of Medicine Office for Continuous Professional Learning, is able to provide AMA PRA Category 1 Credits™, for the live internet activity, and enduring materials credit, for this virtual TB conference.

NTCA, in partnership with Eastern New Mexico University-Roswell, is able to provide continuing education credits for this live internet activity, and enduring materials credit, for this virtual TB conference.

Learning Objectives
  • Describe indications for treatment of LTBI.
  • Describe currently recommended treatment regimens for LTBI and evidence supporting each.
  • Describe the toxicities and monitoring needs to assure safe completion of treatment.
  • List two key features of the newly released LTBI testing and treatment companion document.
Return To Home Page Cyber Poster Hall virtual exhibit hall

Contributors

  • Moderator: John Bernardo

    Dr. Bernardo is a Professor of Medicine and Research Professor of Biochemistry at Boston University School of Medicine. He attends in the Medical Intensive Care Unit and provides pulmonary and allergy clinical consultation services at Boston Medical Center. He is the TB Medical Officer for the Massachusetts Department of Public Health. He is active in local and national TB activities, serving on the Board of the National Tuberculosis Controllers Association (NTCA) as Incidence Level Representative and President, on the NSTC Executive Committee as President, and in Stop TB USA as Board Chair. Dr. Bernardo also is an active member of the Association of Public Health Laboratories Task Force on the Future of TB Laboratory Services.

    Dr. Bernardo has no relevant financial relationships to disclose.

  • Presenter: Robert Belknap

    Dr. Bob Belknap is the Medical Director of the Denver Metro TB Program and an Associate Professor of Medicine in the Division of Infectious Diseases at Denver Health and the University of Colorado. He is past president of the National Tuberculosis Controllers Association (NTCA) and National Society for TB Clinicians (NSTC) and consults with the Curry International TB Center. Dr. Belknap is actively involved in research through the CDC-funded Tuberculosis Trials Consortium (TBTC) and Tuberculosis Epidemiologic Studies Consortium (TBESC). Dr. Belknap was an author of the CDC/NTCA LTBI Treatment Guidelines.

    Dr. Belknap has no relevant financial relationships to disclose.

  • Presenter: Charlie Crane

    Dr. Crane served for many years as the Medical Director for the TB Program, Contra Costa County, California, until his retirement in 2013. He served as President of the California TB Controllers Association (CTCA) on two occasions, and as President of NSTC for two terms. He was an author on many publications and an MMWR report on the molecular epidemiology of an outbreak of TB among crack cocaine users in that jurisdiction, which ultimately included over 100 linked persons with TB over several years. Since his retirement, he has remained active within NTCA. He currently co-chairs the writing group for the Testing and Treatment of Latent Tuberculosis Infection in the United States: Clinical Recommendations.

    Dr. Crane has no relevant financial relationships to disclose.

  • Presenter: Marcos Burgos

    Dr. Marcos Burgos is a Professor of the University of New Mexico School of Medicine and Medical Director of the Tuberculosis program for the New Mexico Department of Health. Dr. Burgos' research focuses on international health, TB control programs, drug-resistant tuberculosis, and molecular epidemiology. He has published original research in these areas. In his role as Medical Director of the TB program, he supervises the care of patients and consults with medical providers to oversee treatment of TB patients in New Mexico. He is currently the Section Chief of Infectious Diseases at the New Mexico VA Health Care System in Albuquerque, New Mexico. Dr. Burgos is a past president of the NSTC and currently co-chairs the writing group for the Testing and Treatment of Latent Tuberculosis Infection in the United States: Clinical Recommendations.

    Dr. Burgos has no relevant financial relationships to disclose.

January 29, 2021
Fri 3:00 PM EST

Duration 2H 0M

This live web event has ended.

For Technical Support
support@blueskyelearn.com
+1 (858) 201-4136